Cargando…

Long-term prognostic factors for PRRT in neuroendocrine tumors

AIM/INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS) rates in the prospective phase III study (NETTER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trautwein, Nils Florian, Schwenck, Johannes, Jacoby, Johann, Reischl, Gerald, Fiz, Francesco, Zender, Lars, Dittmann, Helmut, Hinterleitner, Martina, la Fougère, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288842/ https://www.ncbi.nlm.nih.gov/pubmed/37359009 http://dx.doi.org/10.3389/fmed.2023.1169970

Ejemplares similares

Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
por: Schmidt, Moritz, et al.
Publicado: (2023)

Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies
por: Hinterleitner, Martina, et al.
Publicado: (2021)

Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report
por: Stingu, Elena, et al.
Publicado: (2023)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
por: Harris, Philip E., et al.
Publicado: (2022)

Optimization of Y-90 Radioembolization Imaging for Post-Treatment Dosimetry on a Long Axial Field-of-View PET/CT Scanner
por: Linder, Pia M., et al.
Publicado: (2023)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients
por: Schmidt, Moritz, et al.
Publicado: (2022)

Influence of 99m-Tc-Nanocolloid Activity Concentration on Sentinel Lymph Node Detection in Endometrial Cancer: A Quantitative SPECT/CT Study
por: Sahbai, Samine, et al.
Publicado: (2020)

Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
por: Scalorbi, Federica, et al.
Publicado: (2021)

Long‐term remission of small cell lung cancer after reactivation of tuberculosis following immune‐checkpoint blockade: A case report
por: Sirgiovanni, Mattia, et al.
Publicado: (2021)

Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients
por: Fiz, Francesco, et al.
Publicado: (2017)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

In vivo imaging of CD8(+) T cells in metastatic cancer patients: first clinical experience with simultaneous [(89)Zr]Zr-Df-IAB22M2C PET/MRI
por: Schwenck, Johannes, et al.
Publicado: (2023)

Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
por: Roll, Wolfgang, et al.
Publicado: (2021)

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE
por: Pettersson, Olof Joakim, et al.
Publicado: (2021)

NUT Carcinoma—An Underdiagnosed Malignancy
por: Lauer, Ulrich M., et al.
Publicado: (2022)

The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
por: Michetti, Caterina, et al.
Publicado: (2017)

Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images
por: Fiz, Francesco, et al.
Publicado: (2019)

Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Author Correction: Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
por: Scalorbi, Federica, et al.
Publicado: (2023)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

Functional study and pathogenicity classification of PRRT2 missense variants in PRRT2‐related disorders
por: Zhao, Shao‐Yun, et al.
Publicado: (2019)

Multiparametric Dual-Time-Point [(18)F]FDG PET/MRI for Lymph Node Staging in Patients with Untreated FIGO I/II Cervical Carcinoma
por: Weissinger, Matthias, et al.
Publicado: (2022)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
por: Durmo, Rexhep, et al.
Publicado: (2022)

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression
por: Rittig, Susanne M., et al.
Publicado: (2022)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma
por: Schmidt, Moritz, et al.
Publicado: (2023)

Image Quality and Quantitative PET Parameters of Low-Dose [(18)F]FDG PET in a Long Axial Field-of-View PET/CT Scanner
por: Calderón, Eduardo, et al.
Publicado: (2023)

Platelet-expressed immune checkpoint regulator GITRL in breast cancer
por: Zhou, Yanjun, et al.
Publicado: (2021)

Paroxysmal Dyskinesias in a PRRT2 Mutation Carrier
por: Marano, Massimo, et al.
Publicado: (2018)

First Results and Experience with PRRT in South Africa
por: Vorster, Mariza, et al.
Publicado: (2018)

PRRT2, a network stability gene
por: Michetti, Caterina, et al.
Publicado: (2017)

New Insights in PRRT: Lessons From 2021
por: Puliani, Giulia, et al.
Publicado: (2022)

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
por: Schmitt, Julia, et al.
Publicado: (2022)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Diagnostic Performance of Dynamic Whole-Body Patlak [(18)F]FDG-PET/CT in Patients with Indeterminate Lung Lesions and Lymph Nodes
por: Weissinger, Matthias, et al.
Publicado: (2023)

Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE
por: Basu, Sandip, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_41nbuknvmmlgfgnag3hj9e3ip6